(Q24248026)

27 June 2017

0 references

1 reference

title

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (English)

1 reference

27 June 2017

1 reference

L Sutherland

1

1 reference

PubMed ID

27 June 2017

JK MacDonald

series ordinal

2

0 references

J K MacDonald

series ordinal

2

1 reference

27 June 2017

21 July 2003

0 references

1 January 2003

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

1 reference

27 June 2017

CD000543

1 reference

27 June 2017

3

1 reference

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

27 June 2017

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

An oral preparation to release drugs in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Sulphasalazine in ulcerative colitis: in memoriam?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Cortisone and corticotrophin in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Alternatives to Sulfasalazine: A Meta-analysis of 5-ASA in the Treatment of Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Olsalazine in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Olsalazine in patients intolerant of sulphasalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Pentasa in lieu of sulfasalazine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543

7 January 2021

10.1002/14651858.CD000543

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

2082228

PubMed ID

27 June 2017

2082228

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

2082228

1 reference

PubMed ID